Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SHILPAMED | NSE
-13.70
-3.20%
Healthcare
Drug Manufacturers-Specialty & Generic
31/03/2024
24/04/2026
413.90
434.85
435.35
412.00
Shilpa Medicare Limited together with its subsidiaries engages in the manufacturing and selling active pharmaceutical ingredients (APIs) intermediates and formulations in India the United States Europe and internationally. It's primary oncology and non-oncology APIs include capecitabine gemcitabine hydrochloride axitinib erlotinib hydrochloride and irinotecan hydrochloride as well as ambroxol tranexmic acid and ursodeoxycholic acid; and new drug delivery systems peptides/biotech products specialty chemicals etc. The company also provides contract manufacturing of various dosage forms such as tablets capsules liquid injections lyophilized injectables and sterile dry powder injectables. It is also involved in the wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is headquartered in Raichur India.
View LessPositive Momentum
Low Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
Price Below SMA10D
Smallcap (300M - 2B USD)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
32.1%1 month
39.9%3 months
43.9%6 months
38.0%172.28
196.08
4.67
0.52
0.30
37.98
8.12
-
2.74B
40.87B
427.20M
-
15.89
942.90
12.40
1.79
-
-
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
39.90
Range1M
98.75
Range3M
176.90
Rel. volume
0.73
Price X volume
173.79M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Suven Life Sciences Limited | SUVEN | Drug Manufacturers-Specialty & Generic | 202.05 | 44.65B | -2.70% | n/a | 0.26% |
| RPG Life Sciences Limited | RPGLIFE | Drug Manufacturers-Specialty & Generic | 2033.1 | 33.64B | 1.08% | 50.00 | 0.00% |
| Aarti Drugs Limited | AARTIDRUGS | Drug Manufacturers-Specialty & Generic | 366.7 | 33.51B | -1.41% | 27.18 | 44.03% |
| ZOTA | ZOTA | Biotechnology | 1292.2 | 33.50B | 0.59% | n/a | 105.90% |
| Gufic Biosciences Limited | GUFICBIO | Drug Manufacturers-Specialty & Generic | 298.3 | 29.92B | 0.61% | 50.00 | 62.51% |
| Orchid Pharma Limited | ORCHPHARMA | Drug Manufacturers-Specialty & Generic | 566.85 | 28.86B | 0.01% | 59.92 | 11.56% |
| Bliss Gvs Pharma Limited | BLISSGVS | Drug Manufacturers-Specialty & Generic | 262.68 | 27.66B | -2.27% | 17.04 | 10.32% |
| Dishman Carbogen Amcis Limited | DCAL | Biotechnology | 169.01 | 26.50B | -3.17% | n/a | 41.09% |
| Unichem Laboratories Limited | UNICHEMLAB | Drug Manufacturers-Specialty & Generic | 372.35 | 26.31B | -3.39% | n/a | 10.48% |
| Alembic Limited | ALEMBICLTD | Drug Manufacturers-Specialty & Generic | 91.42 | 23.56B | -2.15% | 12.29 | 0.42% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Vertoz Advertising Limited | VERTOZ | Advertising Agencies | 50.36 | 44.18B | -2.59% | 48.67 | 10.74% |
| "SAI SILKS (KALAMANDIR) LIMITED " | KALAMANDIR | Apparel Retail | 105.44 | 15.54B | -1.25% | 28.83 | 43.67% |
| Signpost India Limited | SIGNPOST | Advertising Agencies | 261.58 | 15.33B | -2.64% | 30.54 | 80.30% |
| V2 Retail Limited | V2RETAIL | Apparel Retail | 203.06 | 7.24B | -2.11% | 120.49 | 191.28% |
| Bhagyanagar India Ltd | BHAGYANGR | Copper | 219.34 | 7.09B | 1.49% | 36.36 | 52.08% |
| Madhav Copper Limited | MCL | Copper | 59 | 1.63B | -1.55% | 82.22 | 32.14% |
| Cubex Tubings Limited | CUBEXTUB | Copper | 89.31 | 1.30B | -1.13% | 35.85 | 21.78% |
| Touchwood Entertainment Limited | TOUCHWOOD | Advertising Agencies | 75.31 | 839.62M | 0.39% | 50.06 | 4.88% |
| Sagardeep Alloys Limited | SAGARDEEP | Copper | 23.58 | 409.35M | -2.16% | 58.62 | 43.14% |
| Heads UP Ventures Limited | HEADSUP | Apparel Retail | 7.29 | 159.72M | 0.00% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 37.98 | 24.85 | Expensive |
| Ent. to Revenue | 8.12 | 11.40 | Cheaper |
| PE Ratio | 172.28 | 51.36 | Expensive |
| Price to Book | 4.67 | 6.83 | Cheaper |
| Dividend Yield | - | 0.52 | - |
| Std. Deviation (3M) | 43.87 | 42.17 | Par |
| Debt to Equity | 0.52 | 0.35 | Expensive |
| Debt to Assets | 0.30 | 0.17 | Expensive |
| Market Cap | 40.87B | 290.82B | Emerging |